Using CD19-targeted CAR-T cell therapy, some researchers successfully treated a patient with anti-synthetase antibody syndrome, who fully recovered from the autoimmune disease without the need for immunosuppressive medications six months after CAR-T cell therapy (98). The gene discussed is CD19; the disease is autoimmune disease.